Total Voting Rights

RNS Number : 5557V

Hikma Pharmaceuticals Plc

16 December 2013

 

Hikma Pharmaceuticals PLC

Voting Rights and Capital

LONDON, 16 December 2013, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 197,967,328 ordinary shares with voting rights. There are 77,000 shares held in treasury (previously 210,000 of which 133,000 have been used to satisfy option awards that have been exercised), which do not carry voting rights and have been excluded from the above figure.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and Transparency Rules.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million. 

 

END

 

 

TVREAKADFSKDFFF